Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Critics on "adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study".

Pae CU.

Psychiatry Investig. 2013 Mar;10(1):98-9. doi: 10.4306/pi.2013.10.1.98. Epub 2013 Feb 8. No abstract available.

2.

Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.

de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, Kunz M, Gomes FA, Giglio LF, Lobato MI, Belmonte-de-Abreu PS, Gama CS.

J Clin Psychiatry. 2009 Oct;70(10):1416-23. doi: 10.4088/JCP.08m04935gry. Erratum in: J Clin Psychiatry. 2011 Aug;72(8):1157.

PMID:
19906345
3.

Lack of association between serum brain-derived neurotrophic factor levels and improvement of schizophrenia symptoms in a double-blind, randomized, placebo-controlled trial of memantine as adjunctive therapy to clozapine.

de Lucena D, Fernandes BS, Kunz M, Fries GR, Stertz L, Aguiar B, Pfaffenseller B, Gama CS.

J Clin Psychiatry. 2010 Jan;71(1):91-2. doi: 10.4088/JCP.09l05388. No abstract available.

PMID:
20129011
4.

A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia.

Friedman JI, Carpenter D, Lu J, Fan J, Tang CY, White L, Parrella M, Bowler S, Elbaz Z, Flanagan L, Harvey PD.

J Clin Psychopharmacol. 2008 Feb;28(1):59-63. doi: 10.1097/jcp.0b013e318161318f.

PMID:
18204342
5.

Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study.

Kumari V, Aasen I, ffytche D, Williams SC, Sharma T.

Neuroimage. 2006 Jan 15;29(2):545-56. Epub 2005 Sep 21.

PMID:
16181792
6.

A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI).

Ferris S, Schneider L, Farmer M, Kay G, Crook T.

Int J Geriatr Psychiatry. 2007 May;22(5):448-55.

PMID:
17117395
7.

Memantine induces reversible neurologic impairment in patients with MS.

Villoslada P, Arrondo G, Sepulcre J, Alegre M, Artieda J.

Neurology. 2009 May 12;72(19):1630-3. doi: 10.1212/01.wnl.0000342388.73185.80. Epub 2008 Dec 17.

PMID:
19092106
8.

Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.

Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP.

J Clin Psychiatry. 2009 Jan;70(1):104-12. Epub 2008 Nov 18. Review.

PMID:
19026265
9.

A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia.

Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H, White L, Parrella M, Davis KL.

Biol Psychiatry. 2002 Mar 1;51(5):349-57.

PMID:
11904128
10.

Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study.

Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, Ernst T, Jarvik JG, Miller EN, Singer EJ, Ellis RJ, Kolson DL, Simpson D, Nath A, Berger J, Shriver SL, Millar LL, Colquhoun D, Lenkinski R, Gonzalez RG, Lipton SA; Adult AIDS Clinical Trial Group (ACTG) 301; 700 Teams; HIV MRS Consortium.

AIDS. 2007 Sep 12;21(14):1877-86.

PMID:
17721095
12.

Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study.

Fagerlund B, Søholm B, Fink-Jensen A, Lublin H, Glenthøj BY.

Clin Neuropharmacol. 2007 Jan-Feb;30(1):3-12.

PMID:
17272964
14.

Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis.

Schmitt FA, van Dyck CH, Wichems CH, Olin JT; Memantine MEM-MD-02 Study Group.

Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):255-62.

PMID:
17132970
15.

Randomized, placebo-controlled, crossover trial of memantine for cognitive changes with corticosteroid therapy.

Brown ES, Vazquez M, Nakamura A.

Biol Psychiatry. 2008 Oct 15;64(8):727-9. doi: 10.1016/j.biopsych.2008.05.010. Epub 2008 Jun 25.

PMID:
18582848
16.

A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia.

Akhondzadeh S, Gerami M, Noroozian M, Karamghadiri N, Ghoreishi A, Abbasi SH, Rezazadeh SA.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Dec 12;32(8):1810-5. doi: 10.1016/j.pnpbp.2008.08.001. Epub 2008 Aug 7.

PMID:
18727948
17.

The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia.

Friedman JI, Ocampo R, Elbaz Z, Parrella M, White L, Bowler S, Davis KL, Harvey PD.

J Clin Psychopharmacol. 2005 Jun;25(3):237-42.

PMID:
15876902
18.

Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease.

Emre M, Mecocci P, Stender K.

J Alzheimers Dis. 2008 Jun;14(2):193-9.

PMID:
18560130
19.

A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study.

Niitsu T, Fujisaki M, Shiina A, Yoshida T, Hasegawa T, Kanahara N, Hashimoto T, Shiraishi T, Fukami G, Nakazato M, Shirayama Y, Hashimoto K, Iyo M.

J Clin Psychopharmacol. 2012 Oct;32(5):593-601. doi: 10.1097/JCP.0b013e3182664cfc.

PMID:
22926591
20.

[Memantine as an adjunctive therapy for schizophrenia negative symptoms].

Gama CS, Antunes P, Moser C, Belmonte-de-Abreu PS.

Rev Bras Psiquiatr. 2005 Sep;27(3):257-8. Epub 2005 Oct 4. Portuguese. No abstract available.

Supplemental Content

Support Center